INmune Bio, Inc. (INMB)

In the past six months, INmune Bio reported Q3 2025 earnings with a net loss of $6.5 million and Q2 2025 earnings with a net loss of $24.5 million. The MINDFuL Phase 2 trial for Alzheimer's disease missed its primary cognitive endpoints in the overall patient population but showed a positive impact in a pre-defined subset. There were management changes, including a new CEO and interim CFO. The company completed a $19 million registered direct offering and its first commercial pilot-scale manufacturing run of CORDStrom in the UK. The share price declined by 68.99% and reached an all-time low.

Specific demand seasonality for INmune Bio's products is not explicitly available. Demand for its potential future commercial products would likely be driven by medical need, regulatory approvals, and market adoption rather than traditional seasonal consumer patterns.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies to reprogram the innate immune system for diseases like cancer and Alzheimer's. Their product pipeline includes the DN-TNF Platform (XPro1595/INB03) to neutralize soluble tumor necrosis factor, the Natural Killer (NK) Cell Priming Platform (INKmune) to eliminate minimal residual disease in cancer patients, and CORDStrom, a platform of human umbilical cord-derived mesenchymal stromal/stem cells.

INmune Bio is headquartered in Boca Raton, Florida, with clinical programs across North America. They have partnered with Cell and Gene Therapy Catapult in the UK to scale up CORDStrom manufacturing.

INmune Bio's reputation has been influenced by mixed results from the MINDFuL Phase 2 trial, the early termination of patient recruitment in the CARE-PC trial, and significant management changes, all of which could impact stakeholder confidence.

INmune Bio's ownership includes institutional investors like BlackRock, Inc. and Vanguard Group Inc., as well as retail and individual investors. Insiders hold approximately 17.01% of the stock, institutional investors hold about 11.65%, and public companies and individual investors own approximately 71.34%.